U.S. markets open in 3 hours 31 minutes

Aptose Biosciences Inc (LTI.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
2.1600-0.0600 (-2.70%)
As of 10:38AM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2200
Bid2.1600 x N/A
Ask2.3000 x N/A
Day's Range2.1600 - 2.1600
52 Week Range1.9900 - 10.4850
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateNov 09, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for LTI.SG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

      SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer. With a healthcare tenure of more than 25 years, Mr. Payne has held several CFO a

    • Insider Monkey

      Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript

      Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript November 9, 2023 Aptose Biosciences Inc. beats earnings expectations. Reported EPS is $-1.76, expectations were $-2.16. Operator: Good afternoon. My name is Hope, and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences Conference Call for the Third […]

    • GlobeNewswire

      Aptose Reports Results for the Third Quarter 2023

      Tuspetinib (TUS) Targets Venetoclax (VEN) Resistance MechanismsTUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated and Wildtype TUS/VEN Overall Response Rate of 48% in Heavily Pre-Treated Relapsed/Refractory AML Patients Tuspetinib Favorable Safety Profile Continues with TUS/VEN Doublet TherapyConference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences